Activity of Novel Ceftibuten-Avibactam, Ceftazidime-Avibactam, and Comparators Against a Challenge Set of Enterobacterales from Outpatient Centers and Nursing Homes Across the United States (2022-2024)
Ceftibuten is being developed in combination with the oral prodrug of avibactam. Outpatient isolates (n = 500) from 11 US states underwent susceptibility testing with manual broth microdilution. Ceftibuten had susceptibility rates of 64% (CLSI) and 23% (EUCAST). Ceftibuten-avibactam achieved 96.4% inhibition at MIC ≤ 1 µg/mL. Susceptibility rates were as follows: cefpodoxime (2.6%), ceftriaxone (1%), ceftazidime-avibactam (99.6%), tebipenem (89%), ertapenem (94.4%), levofloxacin (26.6%), trimethoprim-sulfamethoxazole (40.2%), and fosfomycin (96.8%). Ceftibuten-avibactam demonstrates potent in vitro activity against cephalosporin non-susceptible isolates.
Authors
- Kimberly Taylor (ORCID: https://orcid.org/0000-0002-0095-6403)
- Yungchou Wang
- Aliaa Fouad (ORCID: https://orcid.org/0009-0007-6467-1806)
- Monica Srodon
- Maroun M. Sfeir (ORCID: https://orcid.org/0000-0002-1743-4206)
- Holly Huse (ORCID: https://orcid.org/0009-0004-7586-445X)
- Erik Munson (ORCID: https://orcid.org/0000-0001-5359-6643)
- A Brian Mochon
- Andrew E Clark
- David P Nicolau
- Robin Chamberland
- Lars F Westblade
- Isabella W Martin
- May M Bobenchik
- Tomefa E Asempa
Publication Details
- Journal
- Scholar Commons (University of South Carolina)
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1128/aac.01867-24">https://doi.org/10.1128/aac.01867-24</a></p
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00